Biodexa Pharmaceuticals (BDRX) announced its collaboration partner, Rapamycin Holdings, Emtora Biosciences has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas, CPRIT. This award brings the total grant awarded by CPRIT to support the registrational Phase 3 program of eRapa in familial adenomatous polyposis, FAP, to $20.0 million. “We are sincerely thankful to Emtora, our collaboration partner for their work in preparing the application and, of course, to CPRIT for this additional award.” said Stephen Stamp, CEO and CFO of Biodexa Pharmaceuticals PLC. “This grant will enable us to include more sites, speed up recruitment and, subject to regulatory approval, bring this medicine to patients who currently have no option other than surgical resection of part or all of their GI tract.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals Lowers Warrant Exercise Price to Boost Capital
- Biodexa Pharmaceuticals Secures EU Orphan Drug Designation for eRapa in FAP
- Biodexa Pharmaceuticals receives orphan drug designation in Europe for eRapa
- Biodexa Pharmaceuticals Faces Setback as Key Resolution Fails at General Meeting
- Biodexa Pharmaceuticals Announces General Meeting for Strategic Share Resolutions